Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4612537 | 0.88 | OPRD1 (0.48) | KMT2AOPRK1OPRD1OPRM1ALDH1A1 | |
| SCHEMBL16423921 | 0.84 | SLC6A3 (0.44) | KMT2ASLC6A3OPRK1OPRD1OPRM1 | |
| SCHEMBL16422916 | 0.84 | SLC6A3 (0.44) | KMT2ASLC6A3OPRK1OPRD1OPRM1 | |
| SCHEMBL4924810 | 0.84 | RORC (0.45) | KMT2ASLC6A3 | |
| SCHEMBL4602863 | 0.84 | HSD11B1 (0.38) | KMT2ASLC6A3HSD11B1OPRM1CCR1 | |
| SCHEMBL4603488 | 0.84 | HSD11B1 (0.38) | KMT2ASLC6A3HSD11B1OPRM1CCR1 | |
| SCHEMBL16423480 | 0.83 | KMT2A (0.51) | KMT2ASLC6A3HSD11B1OPRK1OPRD1 | |
| SCHEMBL4666335 | 0.81 | SLC6A3 (0.49) | KMT2ASLC6A3HSD11B1OPRK1OPRD1 | |
| SCHEMBL16422536 | 0.81 | SLC6A3 (0.49) | KMT2ASLC6A3HSD11B1OPRK1OPRD1 | |
| SCHEMBL14046295 | 0.81 | SLC6A3 (0.59) | KMT2ASLC6A3OPRM1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | ANDREWS MARK DAVID | 2008-10-30 | — | — | US | disclosed |
| EP-1928460-A2 | MC4R-AGONISTS FOR THE TREATMENT OF URINARY TRACT DYSFUNCTION | Pfizer Limited (GB) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007015157-A2 | MC4R-AG0NISTS FOR THE TREATMENT OF URINARY TRACT DYSFUNCTION | PFIZER LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | GPR4, GPR119, PRLHR | KMT2A 3354/4885SLC6A3 1030/4885HSD11B1 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.